A comprehensive toolkit for analyzing cell-free DNA genomic sequencing data in liquid biopsy [0.03%]
Junpeng Zhou,Keyao Zhu,Xiaoqian Huang et al.
Junpeng Zhou et al.
By standardizing and accelerating cfDNA analysis, cfDNAanalyzer enables reproducible biomarker discovery and advances translational liquid biopsy research.
Early detection and subtyping of gastric cancer: A cell-free DNA fragmentome-based liquid biopsy method [0.03%]
Yongyi Chen,Haiqi Liao,Yuzhi Liu et al.
Yongyi Chen et al.
Cell-free DNA (cfDNA) in plasma provides attractive opportunities for early cancer diagnosis. This study aimed to establish gastric cancer (GC) artificial intelligence algorithms (GC-AIAs) based on cfDNA fragmentome for GC's early detection...
Yuanchao Cao,Dingyu Rao,Defa Huang et al.
Yuanchao Cao et al.
This review systematically summarizes the recent advances of SERS in detecting key liquid biopsy biomarkers (exosomes, CTCs, ctDNA), critically analyzes its advantages in sensitivity and multiplexing, and discusses the main challenges for clinical translation, including signal interference in complex
Amit Kumar Joseph,Gaurav Khatri,Surapaneni Keerthi Sai et al.
Amit Kumar Joseph et al.
Therefore, it is of interest to investigate the dynamic changes in liquid biopsy markers circulating tumor deoxyribonucleic acid (ctDNA), circulating tumor cells (CTCs), exosomes and micro ribonucleic acids (microRNA) during OSCC treatment.
Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer [0.03%]
Asami Matsunaga,Miho Ogawa,Akiko Kunita et al.
Asami Matsunaga et al.
significantly higher in cases with lymphovascular invasion (p=0.034) and lymph node metastasis (p=0.010), but were not correlated with tumor size, stage, or histologic type. ctHPV DNA was more consistently detectable than PIK3CA hotspot mutations in plasma, supporting its robustness as a biomarker in liquid...biopsy settings.
Michihito Tagawa,Ryohei Yoshitake,Kohei Saeki
Michihito Tagawa
In human medicine, ctDNA has been utilized as a liquid biopsy tool and a noninvasive biomarker for the early diagnosis, prognosis, and management of several tumors.
SERS analysis of cancer cell-derived exosome phenotypes using a rare-earth ion coordination-dominated exosome capture strategy [0.03%]
Yan Zhou,Guangyao Wu,Lili Cong et al.
Yan Zhou et al.
Exosomes are important liquid biopsy markers for non-invasive cancer diagnosis, making efficient exosome isolation and precise detection particularly crucial.
A paper-based fluorescent biosensing platform for miRNA detection with dual high-throughput and smartphone readout [0.03%]
Marianna Rossetti,Ruslán Alvarez-Diduk,Liming Hu et al.
Marianna Rossetti et al.
The detection of oligonucleotide biomarkers in biological fluids is central to modern diagnostics, particularly for minimally invasive liquid biopsy approaches.
Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma [0.03%]
Victor Robic,Maxime Collin,Jules Dupont et al.
Victor Robic et al.
Background: Tumor volumetry and liquid biopsy are emerging tools reflecting tumor burden and enhancing prognostic assessment in advanced pancreatic ductal adenocarcinoma (PDAC).
Highly sensitive detection of miRNA-21 in human serum via adjustable circular dichroism from chiral helical gold nanorods [0.03%]
Cannan Zhao,Shuai Wen,Yusheng Feng et al.
Cannan Zhao et al.
The chiral CD transduction strategy pioneers a new paradigm for miRNA analysis by synergizing chiral nanomaterial and enhanced signal transduction with cascade amplification, offering significant potential for clinical liquid biopsy applications.
耗时 0.20056 秒，为您在
49809647
条记录里面共找到 7073 篇文章 [XML]